Chronic PainHealthy VolunteersMicrodosingDepressive DisordersAnxiety DisordersSubstance Use Disorders (SUD)FibromyalgiaHeadache Disorders (Cluster & Migraine)LSDPsilocybin

Potential analgesic effects of psychedelics on select chronic pain conditions: A survey study

A survey of patients with fibromyalgia, arthritis, migraine, tension‑type headache and sciatica found that psychedelic use—especially full doses—was reported to give greater pain relief than conventional medications in all conditions except sciatica; microdoses improved migraine and matched conventional treatment for the other non‑sciatica conditions. These results suggest full and microdoses of classical psychedelics may merit further investigation as treatments for select chronic pain disorders.

Authors

  • Kim Kuypers
  • Johannes Ramaekers
  • Amanda Feilding

Published

European Journal of Pain
individual Study

Abstract

Background

Chronic pain is a major cause of suffering and disability and is often associated with psychiatric complications. Current treatments carry the risk of severe side effects and may lead to limited or no relief at all in a relevant portion of this patient population. Preliminary evidence suggests that classical psychedelics (e.g. LSD and psilocybin) may have analgesic effects in healthy volunteers, and in certain chronic pain conditions and observational studies reveal that they are used in naturalistic settings as a means to manage pain.

Methods

In order to gain insight on the effectiveness of such compounds in chronic pain conditions, we set up a survey addressed to chronic pain patients inquiring about psychedelic use and the relief levels achieved with both conventional treatments, full psychedelic doses and microdoses. We analysed data related to five conditions selected based on diagnostic homogeneity within each of them: fibromyalgia, arthritis, migraine, tension‐type headache and sciatica.

Results

Except for sciatica, volunteers reported that psychedelics led to better pain relief compared to conventional medication in all examined conditions. More specifically, full doses performed better than conventional medication. Microdoses led to significantly better relief compared to conventional medication in migraines and achieved comparable relief in the remaining three categories. Implications for future research are discussed.

Conclusions

Full doses and microdoses may hold value in the treatment of some specific chronic pain conditions.

Significance

Psychedelic substances are receiving increasing attention from the scientific literature because of evidence showing beneficial effects on several measures related to mental health in clinical samples and healthy volunteers samples. Previous evidence suggests that people suffering from chronic pain are using psychedelics to seek relief and the present paper presents the results of a survey study investigating their use and analgesic effects among individuals suffering from fibromyalgia, arthritis, migraine, tension‐type headache and sciatica.

Available with Blossom Pro

Research Summary of 'Potential analgesic effects of psychedelics on select chronic pain conditions: A survey study'

Introduction

Chronic pain (CP) affects about 20% of the population, is a leading cause of disability and frequently co-occurs with psychiatric symptoms such as depression and anxiety. Standard pharmacological treatments (NSAIDs, opioids, anticonvulsants, antidepressants) and psychological therapies provide incomplete relief for many people living with chronic pain (PLCP), and some options—most notably opioids—carry substantial risks including dependence and opioid-induced hyperalgesia. Against this backdrop, classic serotonergic psychedelics (for example LSD and psilocybin) have re-emerged in research and anecdotal reports as candidate treatments for pain, with historical clinical data, experimental work in healthy volunteers and observational reports suggesting possible analgesic and prophylactic effects at both full (psychoactive) doses and low or ‘‘micro’’ doses. Cavarra and colleagues set up an online survey to capture self-reported analgesic effects of psychedelic use in people who have experienced CP and who had used psychedelics. The present paper focuses on five pain conditions chosen for within-category diagnostic homogeneity: fibromyalgia (FM), arthritis, migraine, tension-type headache (TTH) and sciatica. The study aimed to compare perceived pain relief from conventional treatments, psychedelic microdoses and psychedelic full doses, and to explore whether mood changes or expectations explained any reported analgesia. The authors frame this naturalistic work as a first step to inform controlled investigation of dose, frequency, condition specificity and mechanisms.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Pro members can view the original manuscript directly in the browser.

Study Details

References (12)

Papers cited by this study that are also in Blossom

82 cited
21 cited
Psychedelic-Assisted Psychotherapy-A Systematic Review of Associated Psychological Interventions

Cavarra, M., Falzone, A., Ramaekers, J. G. et al. · Frontiers in Psychology (2022)

Beating Pain with Psychedelics: Matter over Mind?

Elman, I., Borsook, D., Pustilink, A. · Neuroscience and Biobehavioral Reviews (2022)

Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia

Glynos, N. G., Pierce, J., Davis, A. K. et al. · Journal of Psychoactive Drugs (2022)

LSD-assisted psychotherapy in patients with terminal cancer

Grof, S., Goodman, L. E., Richards, W. A. · Pharmacopsychiatry (1973)

The therapeutic potential of microdosing psychedelics in depression

Kuypers, K. P. C. · Therapeutic Advances in Psychopharmacology (2020)

Microdosing psychedelics: More questions than answers? An overview and suggestions for future research

Kuypers, K. P. C., Erritzoe, D., Knudsen, G. M. et al. · Journal of Psychopharmacology (2019)

A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers

Ramaekers, J. G., Hutten, N. P. W., Mason, N. L. et al. · Journal of Psychopharmacology (2020)

74 cited
Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey

Schindler, E. A. D., Gottschalk, C. H., Weil, M. J. et al. · Journal of Psychoactive Drugs (2015)

91 cited
Show all 12 references
Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin

Schindler, E. A. D., Sewell, R. A., Gottschalk, C. H. et al. · Neurotherapeutics (2021)

Cited By (1)

Papers in Blossom that reference this study

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.